Clinical benefit as a primary efficacy endpoint

被引：8

作者：

Ballatori, E ^{[1
]}

Del Favero, A

Roila, F

机构：

[1] Univ Aquila, I-67100 Laquila, Italy

[2] Univ Perugia, I-06100 Perugia, Italy

[3] Policlin Hosp, Perugia, Italy

来源：

JOURNAL OF CLINICAL ONCOLOGY | 1998年 / 16卷 / 02期

关键词：

D O I：

10.1200/JCO.1998.16.2.803

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

收藏

页码：803 / 804

页数：2

相关论文

共 3 条

[1] Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial [J].

Burris, HA ;

Moore, MJ ;

Andersen, J ;

Green, MR ;

Rothenberg, ML ;

Madiano, MR ;

Cripps, MC ;

Portenoy, RK ;

Storniolo, AM ;

Tarassoff, P ;

Nelson, R ;

Dorr, FA ;

Stephens, CD ;

VanHoff, DD .

JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (06) :2403-2413

[2]

DEANGELIS V, 1994, SUPPORT CARE CANCER, V2, P171

[3] Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points [J].

Tannock, IF ;

Osoba, D ;

Stockler, MR ;

Ernst, DS ;

Neville, AJ ;

Moore, MJ ;

Armitage, GR ;

Wilson, JJ ;

Venner, PM ;

Coppin, CML ;

Murphy, KC .

JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (06) :1756-1764